Sign in to view content

Low rates of endophthalmitis with intravitreal aflibercept in real world Canadian practice - data from the large prospective study PEGASUS.

Michael Peter Fielden, MD, FRCS(C)

Video
Published 2019

Related

Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Reduced Incidence of Post-Injection Endophthalmitis With Pre-filled Syringes
Daniel B. Roth, MD
On Demand Cases, Courses, and Papers
2020
Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial
Carl J Danzig, MD
Annual Meeting Talks
2020

Category: Inflammatory and Infectious Diseases

See more